Arrhythmias & electrophysiologyMeta-analysis
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
- Systematic review and meta-analysis of randomised trials
- meta-regression
Authors' conclusion
Treatment with semaglutide significantly reduces the incidence of new-onset AF.
Study context
- Population
- Participants in randomized clinical trials (RCTs) of semaglutide
- Participants
- 48,583 participants · 26 RCTs
- Comparison
- Semaglutide vs control
- Semaglutiden = 25,879
- Outcome
- New-onset AF
Pooled result
As reported in the abstract
Odds ratio
0.83
95% CI 0.70–0.98
P = 0.03
Semaglutide vs Controls
OR 0.83 (95% CI 0.70–0.98); P = 0.03
- New-onset atrial fibrillation (AF) events
- 541
Further pooled results
New-onset AF, oral formulation (subgroup)
- Oral formulation reduced AF incidence by 52% (OR 0.48, 95% CI 0.24-0.95)
- P = 0.04
New-onset AF, trials with active comparators (subgroup)
- Active comparator trials: 59% reduction in AF risk (OR 0.41, 95% CI 0.20-0.83)
- P = 0.01
New-onset AF, trials without concomitant SGLT2i therapy (subgroup)
- Significant 21% reduction in new-onset AF (OR 0.79, 95% CI, 0.63-0.99)
- P = 0.04
Meta-regression: baseline covariates (incl. BMI, HbA1c)
- No influence of baseline covariates, including BMI and HbA1c
Meta-regression: % of patients on SGLT2i as moderator
- No statistically significant association
- P = 0.336
Original publication
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials. Eur J Prev Cardiol. Published 28 April 2025. doi:10.1093/eurjpc/zwaf257
Summarised from the published abstract; every number is checked against it